John B. Henneman III, Director at Anika Therapeutics, Inc. (ANIK), bought 2,000 shares at $42.86 ($86K) on 2021-05-18, disclosed to the SEC on 2021-05-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| APRE | BUY | 2024-03-14 | $100K | — | Filing → |
| RCM | SELL | 2023-08-09 | $1.7M | — | Filing → |
| SPNE | SELL | 2020-08-05 | $150K | — | Filing → |